

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2017

Downregulation of lysyl oxidase protects retinal endothelial cells from high glucose–induced apoptosis

Dongjoon Kim
Boston University

Robert P. Mecham
Washington University School of Medicine in St. Louis

Philip C. Trackman
Boston University

Sayon Roy
Boston University

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Kim, Dongjoon; Mecham, Robert P.; Trackman, Philip C.; and Roy, Sayon, "Downregulation of lysyl oxidase protects retinal endothelial cells from high glucose–induced apoptosis." *Investigative Ophthalmology & Visual Science*. 58, 5. 2725–2731. (2017).

https://digitalcommons.wustl.edu/open_access_pubs/7207

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Downregulation of Lysyl Oxidase Protects Retinal Endothelial Cells From High Glucose–Induced Apoptosis

Dongjoon Kim,^{1,2} Robert P. Mecham,³ Philip C. Trackman,⁴ and Sayon Roy^{1,2}

¹Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States

²Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States

³Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States

⁴Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, United States

Correspondence: Sayon Roy, Departments of Medicine and Ophthalmology, Boston University School of Medicine, 650 Albany Street, Boston, MA 02118, USA; sayon@bu.edu.

Submitted: December 20, 2016

Accepted: April 18, 2017

Citation: Kim D, Mecham RP, Trackman PC, Roy S. Downregulation of lysyl oxidase protects retinal endothelial cells from high glucose–induced apoptosis. *Invest Ophthalmol Vis Sci.* 2017;58:2725–2731. DOI: 10.1167/iovs.16-21340

PURPOSE. To investigate the effect of reducing high glucose (HG)-induced lysyl oxidase (LOX) overexpression and increased activity on retinal endothelial cell apoptosis.

METHODS. Rat retinal endothelial cells (RRECs) were grown in normal (N) or HG (30 mM glucose) medium for 7 days. In parallel, RRECs were grown in HG medium and transfected with LOX small interfering RNA (siRNA), scrambled siRNA as control, or exposed to β -aminopropionitrile (BAPN), a LOX inhibitor. LOX expression, AKT activation, and caspase-3 activity were determined by Western blot (WB) analysis and apoptosis by differential dye staining assay. Moreover, to determine whether diabetes-induced LOX overexpression alters AKT activation and promotes apoptosis, changes in LOX expression, AKT phosphorylation, caspase-3 activation, and Bax expression were assessed in retinas of streptozotocin (STZ)-induced diabetic mice and LOX heterozygous knockout (LOX^{+/-}) mice.

RESULTS. WB analysis indicated significant LOX overexpression and reduced AKT activation under HG condition in RRECs. Interestingly, when cells grown in HG were transfected with LOX siRNA or exposed to BAPN, the number of apoptotic cells was significantly decreased concomitant with increased AKT phosphorylation. Diabetic mouse retinas exhibited LOX overexpression, decreased AKT phosphorylation, and increased Bax and caspase-3 activation compared to values in nondiabetic mice. In LOX^{+/-} mice, reduced LOX levels were observed with increased AKT activity, and reduced Bax and caspase-3 activity. Furthermore, decreased levels of LOX in the LOX^{+/-} mice was protective against diabetes-induced apoptosis.

CONCLUSIONS. Findings from this study indicate that preventing LOX overexpression may be protective against HG-induced apoptosis in retinal vascular cells associated with diabetic retinopathy.

Keywords: lysyl oxidase, apoptosis, high glucose, AKT, retinal endothelial cells

Diabetic retinopathy, the leading cause of vision loss in the working-age population,^{1,2} is characterized by early vascular lesions such as the formation of acellular capillaries (AC) and pericyte loss (PL),^{3–8} which can contribute to retinal dysfunction. Studies suggest that retinal vascular basement membrane (BM) thickening, a histologic hallmark of diabetic retinopathy,^{9–12} may promote apoptosis and thus lead to vascular cell loss.^{13–15} Our recent study suggests that lysyl oxidase (LOX), a cross-linking enzyme critical for the development and maturation of the BM, is upregulated in rat retinal endothelial cells (RRECs) grown in high-glucose (HG) medium and in diabetic rat retinas.¹⁶ Moreover, excess LOX has been shown to be involved in promoting endothelial cell monolayer permeability.¹⁶ However, the involvement of LOX in mediating HG-induced apoptosis and subsequent retinal vascular cell loss is not well understood.

LOX is synthesized as a 50-kD, N-glycosylated proenzyme (pro-LOX), which undergoes proteolytic cleavage resulting in a 32-kD, catalytically active, and mature enzyme (LOX).^{17,18} The integrity, stability, and functionality of the BM are largely dependent on proper cross-linking of collagen as these cross-

links contribute to the physical and mechanical properties of collagen fibrils in forming a stable BM assembly.^{19,20} LOX plays a critical role in the posttranslational modification of collagen to form covalent cross-links that stabilize insoluble collagen, thus forming a functional extracellular matrix (ECM).^{21–23} However, excess cross-linking mediated by LOX can lead to BM thickening and compromised functionality due to the formation of disorganized assembly of the collagen fibrils, promoting abnormal ECM accumulation in fibrotic diseases.^{24,25} As the BM undergoes histologic and biochemical changes induced by HG insult, the development of AC and PL is exacerbated by the abnormally thickened BM, ultimately progressing to early-stage diabetic retinopathy.

While LOX is primarily known for its role in cross-linking, recent studies indicate that increased LOX levels can promote apoptosis. LOX upregulation may compromise the AKT signaling pathway in human osteosarcoma cells and *ras*-transformed NIH 3T3 cells,^{26,27} thereby promoting apoptosis. LOX was also identified as a tumor suppressor gene,^{28,29} further suggesting that LOX overexpression may trigger apoptosis. However, it is currently unknown whether LOX overexpression



promotes retinal vascular cell loss associated with diabetic retinopathy.

The present study investigated whether HG-induced abnormal LOX overexpression may contribute to apoptosis, and whether reducing HG-induced LOX overexpression may facilitate AKT pathway activity and thereby prevent apoptosis in retinal endothelial cells. Additionally, to determine whether changes seen in LOX expression under HG condition were present *in vivo*, the retinas of LOX^{+/-} mice as well as those of streptozotocin (STZ)-induced diabetic mice were examined.

METHODS

Cell Culture

Capillary endothelial cells derived from rat retinas (RRECs) confirmed positive for von Willebrand factor (vWF) were used in this study, and were isolated as previously described.³⁰ To determine the effect of abnormal LOX overexpression and apoptosis, RRECs were grown in normal (N, 5 mM glucose) or high-glucose (HG, 30 mM glucose) Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Sigma-Aldrich Corp., St. Louis, MO, USA), antibiotics, and antimycotics for 7 days. To determine the effect of reducing LOX overexpression on cell viability, RRECs were grown in HG medium and transfected with LOX small interfering RNA (siRNA), or scrambled (Scram) siRNA as control. Cells from the experimental groups were then assayed for LOX expression, AKT activity, and caspase-3 activation.

Animals

All animal studies were performed in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Twelve wild-type (WT) C57/BL6 albino male mice (Harlan Lab, Inc., Indianapolis, IN, USA) and 12 LOX^{+/-} mice bred into the C57/BL6 albino background kindly provided by Robert Mecham³¹ were used in the study. Genotypes were determined by polymerase chain reaction (PCR) at weaning using tail tip DNA, and then again at the time animals were killed. PCR reactions were performed with a PCR enzyme blend (PCR Master Mix; Promega, Madison, WI, USA) and included the following primers: primer 1, 5'-ACGGCTTGTTGTAAGTCAAA-3'; primer 2, 5'-TGAATGAAGTGCAGACGAG-3'; primer 3, 5'-ATCTGAGTCCCGGTCTTCCT-3'; primer 4, 5'-AGGTCCGGGAGACCTAAAGA-3'. Primers 1 and 2 amplify an approximately 1500-bp fragment from the LOX^{+/-} allele. Primers 3 and 4 amplify a 1022-bp fragment from the WT LOX allele. The LOX^{-/-} genotype was not used because it is perinatal lethal.^{31,32}

Six WT mice and six LOX^{+/-} mice were injected intraperitoneally with STZ (55 mg/kg body weight) to induce diabetes. The glucose concentrations in blood and urine were checked after 2 or 3 days following STZ injection to confirm diabetes status in the animals. The remaining six WT and six LOX^{+/-} animals served as nondiabetic controls. Blood glucose levels were measured in each animal two or three times weekly and at the time of death. The diabetic group represented mice with blood glucose levels of ~350 mg/dL. The diabetic mice received neutral protamine Hagedorn (NPH) insulin injection as needed to maintain blood glucose levels ~350 mg/dL. After 8 weeks of diabetes, all animals were killed, retinas were isolated, and total protein was extracted. To examine the effect of diabetes on LOX, AKT, phosphorylated AKT (p-AKT), cleaved caspase-3, and Bax protein expression, protein isolated from diabetic mouse retinas and nondiabetic mouse retinas was subjected to Western blot (WB) analysis.

Cell Transfection With LOX siRNA and β -Aminopropionitrile (BAPN) Treatment

To determine the effect of reduced LOX expression on cell survival, RRECs were grown in HG medium and transfected with 33 nM LOX siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or 20 μ M Scram siRNA (Qiagen, Valencia, CA, USA) as a negative control in the presence of 8 μ M Lipofectin (Invitrogen, Carlsbad, CA, USA). In this study, an optimal concentration of 33 nM LOX siRNA was used to achieve approximately 40% reduction in LOX expression in RRECs, as supported by our previous study.¹⁶ Additionally, to determine whether LOX activity influences cell survival, cells were exposed overnight to 500 μ M BAPN (Sigma-Aldrich Corp.), a potent inhibitor of LOX activity,³³ 24 hours prior to harvest.

Western Blot Analysis

To determine the expression of LOX, AKT, AKT phosphorylation, and caspase-3 activation, protein isolated from RRECs grown in N or HG medium were subjected to WB analysis. Similarly, protein samples isolated from diabetic or nondiabetic mouse retinas were subjected to WB analysis to examine LOX, AKT, AKT phosphorylation, cleaved caspase-3, and Bax expression. RRECs grown in N or HG medium, or retinal tissues of diabetic or nondiabetic mice, were washed with PBS and lysed in buffer containing 10 mM Tris, pH 7.5 (Sigma-Aldrich Corp.), 1 mM EDTA, and 0.1% Triton X-100 (Sigma-Aldrich Corp.) to yield total protein. Lysates were centrifuged at 13,000g for 20 minutes at 4°C. Protein samples from cell lysates and retinal tissues were then measured by bicinchoninic acid protein assay (Pierce Chemical, Rockford, IL, USA). An equal amount of protein (20 μ g) was loaded in each lane and electrophoresed together with molecular weight standards (Bio-Rad, Hercules, CA, USA) in separate lanes on a 10% SDS-polyacrylamide gel. After electrophoresis, the proteins were transferred onto PVDF membranes (Millipore, Billerica, MA, USA) according to Towbin's procedure³⁴ using a semi-dry apparatus. The membrane was blocked with 5% nonfat dry milk for 2 hours and incubated overnight at 4°C with rabbit polyclonal LOX antibody (1:2000, Catalog No. NB110; Novus, Littleton, CO, USA), rabbit polyclonal Ser473 phosphorylated AKT (p-AKT) antibody (1:2000, Catalog No. 9271; Cell Signaling, Danvers, MA, USA), AKT antibody (1:1000, Catalog No. 9272; Cell Signaling), cleaved caspase-3 antibody (1:1000, Catalog No. 9661; Cell Signaling), or Bax antibody (1:500, Catalog No. 2772; Cell Signaling) solution in Tris-buffered saline containing 0.1% Tween-20 (TTBS) and 5% BSA. The following day, the membrane was washed with TTBS and incubated with a secondary antibody solution containing anti-rabbit IgG, AP-conjugated antibody (1:3000, Catalog No. 7054; Cell Signaling) for 1 hour in room temperature. After washing with TTBS, the membrane was subjected to Immuno-Star chemiluminescent substrate (Bio-Rad) and exposed to X-ray film (Fujifilm, Tokyo, Japan). The amount of protein loaded in the gel lanes was confirmed through Ponceau-S staining after transfer and by β -actin antibody (1:1000, Catalog No. 4967; Cell Signaling). To determine LOX, p-AKT, AKT, cleaved caspase-3, Bax, and β -actin protein expression, densitometric analysis of the chemiluminescent signal was performed at nonsaturating exposures and analyzed using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD, USA).

Differential Staining Assay to Identify Apoptotic Cells

To identify apoptotic cells, a differential dye staining method³⁵ was performed, which relies on the uptake of fluorescent dyes,

acridine orange (AO) and ethidium bromide (EB).³⁶ The condition of the cell membrane integrity and the properties of the DNA binding dyes facilitate the distinction of viable versus early- or late-stage apoptotic cells.³⁶ RRECs grown on coverslips as specified in the experimental conditions were exposed to a dye mixture containing 25 μ g/mL ethidium bromide (Catalog No. E-8751; Sigma-Aldrich Corp.) and 25 μ g/mL acridine orange (Catalog No. A-6014; Sigma-Aldrich Corp.) for 10 minutes, washed with PBS, fixed, and mounted in SlowFade Antifade Kit (Catalog No. S2828; Invitrogen, Eugene, OR, USA). The cells were then visualized using a 4',6-diamidino-2-phenylindole (DAPI) filter, and imaged using a digital camera attached to a fluorescence microscope (Nikon Diaphot, Tokyo, Japan). Ten random fields of approximately 1000 cells/field per sample were counted. Data are pooled from four independent experiments. The number of apoptotic cells per field was expressed as a percentage of the total number of cells in the field, also known as the apoptotic index.³⁶ Apoptotic cells appear orange or bright green while viable cells appear uniformly dark green.

Statistical Analysis

All data are expressed as mean \pm standard deviation (SD). Values of the control groups were normalized to 100%, and values from all other groups were expressed as percentages of control. Statistical analysis was performed using the normalized values. Comparisons between groups were performed using 1-way ANOVA followed by Bonferroni's post hoc test. A level of $P < 0.05$ was considered statistically significant.

RESULTS

Effect of HG on LOX Protein Expression in RRECs

RRECs grown in HG medium had significantly increased LOX expression compared to cells grown in N medium ($163 \pm 23\%$ of N versus $100 \pm 17\%$ of N; $P < 0.05$; $n = 4$; Figs. 1A, 1B). In addition, cells grown in HG medium and transfected with LOX siRNA showed significantly reduced LOX expression compared to cells grown in HG alone ($124 \pm 8\%$ of N versus $163 \pm 23\%$ of N; $P < 0.05$; $n = 4$; Figs. 1A, 1B). As expected, cells grown in HG medium transfected with Scram siRNA did not show a significant difference in LOX expression compared to cells grown in HG medium alone ($165 \pm 12\%$ of N versus $163 \pm 23\%$ of N; $P > 0.05$; $n = 4$; Figs. 1A, 1B).

Effect of HG and LOX Downregulation on AKT Activity and Caspase-3 Activation in RRECs

Western blot analysis indicated that the ratio of p-AKT to total AKT was significantly decreased in cells grown in HG medium compared to those grown in N medium ($65.8 \pm 12.3\%$ of N versus $100 \pm 7.01\%$ of N, $P < 0.05$; $n = 4$; Figs. 1A, 1C). Interestingly, reducing LOX overexpression improved the ratio of p-AKT to AKT, indicating that AKT activity was restored. Cells grown in HG medium and transfected with LOX siRNA showed a significantly improved ratio of p-AKT to AKT compared to cells grown in HG alone ($90.1 \pm 12.9\%$ of N versus $65.8 \pm 12.3\%$ of N; $P < 0.05$; $n = 4$; Figs. 1A, 1C). As expected, cells grown in HG medium transfected with Scram siRNA did not show a significant difference in the ratio of p-AKT to AKT compared to cells grown in HG medium alone ($68.9 \pm 11.4\%$ of N versus $65.8 \pm 12.3\%$ of N; $P > 0.05$; $n = 4$; Figs. 1A, 1C). Moreover, cells grown in HG medium exhibited significantly increased caspase-3 activation ($153.0 \pm 27.1\%$ of N; $P < 0.05$; $n = 4$;

Figs. 1A, 1D). Importantly, cells grown in HG medium and transfected with LOX siRNA showed reduced caspase-3 activation compared to cells grown in HG medium ($102.3 \pm 11.4\%$ of N; $P < 0.05$; $n = 4$; Figs. 1A, 1D).

Reduced LOX Expression and Activity Protect Against HG-Induced Apoptosis in RRECs

Differential dye staining indicated that the cells grown in HG medium showed significantly increased number of apoptotic cells compared to those grown in N medium (4.10 ± 0.53 cells per 100 cells versus 1.83 ± 0.14 cells per 100 cells; $P < 0.05$; $n = 4$; Figs. 2A, 2B, 2E). Interestingly, cells grown in HG medium transfected with LOX siRNA exhibited a significantly reduced number of apoptotic cells compared to cells grown in HG medium alone (2.74 ± 0.26 cells per 100 cells versus 4.10 ± 0.53 cells per 100 cells; $P < 0.05$; $n = 4$; Figs. 2B, 2C, 2E). RRECs grown in HG medium transfected with Scram siRNA did not show a significant difference in the number of apoptotic cells compared to cells grown in HG medium alone (4.15 ± 0.16 cells per 100 cells versus 4.10 ± 0.53 cells per 100 cells; $P > 0.05$; $n = 4$; Figs. 2C, 2D, 2E).

Reduced LOX Activity Rescues AKT Activity and Protects Against HG-Induced Apoptosis in RRECs

To determine whether reduced LOX activity alters AKT activity and influences cell survival, WB analysis and differential dye staining assay were performed. Interestingly, cells grown in HG medium and exposed to BAPN exhibited a significant increase in the ratio of p-AKT to total AKT compared to cells grown in HG medium alone ($63.0 \pm 10.9\%$ of N versus $44.1 \pm 8.5\%$ of N; $P < 0.05$; $n = 4$; Figs. 3A, 3B). Differential dye staining data indicated that cells grown in HG medium showed a significantly increased number of apoptotic cells compared to those grown in N medium (3.16 ± 0.39 cells per 100 cells versus 1.38 ± 0.40 cells per 100 cells; $P < 0.05$; $n = 4$; Figs. 4A, 4B, 4D). Furthermore, cells grown in HG medium and exposed to BAPN exhibited significantly reduced number of apoptotic cells compared to cells grown in HG medium alone (2.12 ± 0.52 cells per 100 cells versus 3.16 ± 0.39 cells per 100 cells; $P < 0.05$; $n = 4$; Figs. 4B, 4C, 4D).

Reducing Diabetes-Induced LOX Overexpression Restores AKT Activity and Inhibits Apoptosis in Mouse Retinas

To determine the effect of diabetes on LOX expression and AKT activity in diabetic mouse retinas, and also whether reducing diabetes-induced LOX overexpression alters AKT activity and caspase-3 activation in diabetic LOX^{+/+} mouse retinas, WB was performed. As expected, WB analysis revealed that the diabetic mouse retinas showed a significant increase in LOX expression compared to nondiabetic mouse retinas ($145 \pm 21\%$ of WT versus $100 \pm 30\%$ of WT; $P < 0.05$; $n = 6$; Figs. 5A, 5B). Additionally, the LOX^{+/+} mice showed a decrease in retinal LOX levels compared with those of control mice ($64 \pm 13\%$ of WT versus $100 \pm 30\%$ of WT; $P < 0.05$; $n = 6$; Figs. 5A, 5B). Importantly, diabetic mouse retinas exhibited a significant decrease in the ratio of p-AKT to total AKT ($56.5 \pm 19\%$ of WT versus $100 \pm 9.7\%$ of WT, $P < 0.05$; $n = 6$; Figs. 5A, 5C) as well as a significant increase in cleaved caspase-3 expression ($181 \pm 31\%$ of WT versus $100 \pm 20\%$ of WT, $P < 0.05$; $n = 6$; Figs. 5A, 5D) and Bax expression ($150 \pm 14\%$ of WT versus $100 \pm 23\%$ of WT, $P < 0.05$; $n = 6$; Figs. 5A, 5E) compared to nondiabetic mouse retinas. Interestingly, reducing LOX overexpression improved the ratio of p-AKT to AKT,




FIGURE 1. Effects of HG and LOX downregulation on AKT activity in RRECs. (A) Representative WB image shows that LOX expression is significantly increased in HG condition. The ratios of p-AKT to AKT were significantly decreased in cells grown in HG medium and in cells grown in HG medium transfected with Scram siRNA. Interestingly, reducing LOX overexpression improved the ratio of p-AKT to AKT. (B) Graphic illustration of cumulative data shows that LOX siRNA significantly reduced LOX expression. (C) Graphic illustration of cumulative data shows ratios of p-AKT to AKT significantly increased in cells grown in HG medium transfected with LOX siRNA compared to cells grown in HG medium or cells grown in HG medium transfected with Scram siRNA. (D) Graphic illustration of cumulative data shows that LOX siRNA significantly reduced cleaved caspase-3 expression. Data are expressed as mean \pm SD. *N versus HG; $P < 0.05$. **HG+LOX siRNA versus HG+Scram siRNA; $P < 0.05$. $n = 4$.

indicating that AKT activity was restored. Retinas of diabetic LOX^{+/−} mice showed a significantly improved ratio of p-AKT to AKT ($77.5 \pm 12\%$ of WT versus $56.5 \pm 19\%$ of WT; $P < 0.05$; $n = 6$; Figs. 5A, 5C) as well as decreased cleaved caspase-3 expression ($115 \pm 6\%$ of WT versus $181 \pm 31\%$ of WT; $P < 0.05$; $n = 6$; Figs. 5A, 5D) and reduced Bax expression ($114 \pm 18\%$ of WT versus $150 \pm 14\%$ of WT; $P < 0.05$; $n = 6$; Figs. 5A, 5E) compared to diabetic mouse retinas.

DISCUSSION

The present study demonstrates that retinal endothelial cells grown in HG medium exhibit abnormal LOX overexpression and decreased AKT phosphorylation concomitant with caspase-3 activation. Similarly, retinas of diabetic mice show LOX upregulation, compromised AKT phosphorylation, and caspase-3 and Bax activation. Interestingly, when LOX upregulation




FIGURE 2. LOX downregulation protects RRECs from HG-induced apoptosis. (A–D) Representative images of cells undergoing apoptosis (arrows): (A) Normal, (B) HG, (C) HG+LOX siRNA, (D) HG+Scram siRNA. Scale bar: 50 μ m. Differential staining assay shows that cells under HG condition undergo increased apoptosis, which was prevented by reducing LOX overexpression. (E) Graphic illustration of cumulative data shows that downregulation of LOX expression rescues RRECs from HG-induced apoptosis. Data are expressed as mean \pm SD. *N versus HG; $P < 0.05$. **HG+LOX siRNA versus HG+Scram siRNA; $P < 0.05$. $n = 4$.




FIGURE 3. Inhibiting increased LOX activity rescues AKT signaling in RRECs. (A) Representative WB image shows that the ratio of p-AKT to AKT was significantly decreased in cells grown in HG medium. Interestingly, inhibiting HG-induced increased LOX activity significantly increased the ratio of p-AKT to AKT. (B) Graphic illustration of cumulative data shows ratios of p-AKT to AKT significantly increased in cells grown in HG medium treated with BAPN compared to cells grown in HG medium alone. Data are expressed as mean \pm SD. *N versus HG; $P < 0.01$. **HG versus HG+BAPN; $P < 0.05$. $n = 4$.

lation is reduced to near normal levels using LOX siRNA or when LOX level is decreased due to allele knockout strategies, such as the LOX^{+/-} mice used in the current study, we observed restoration of AKT activity, suggesting a direct link between LOX expression and AKT activation. In addition, when HG-induced increased LOX activity was reduced using BAPN, AKT activity was improved. To our knowledge, this is the first study showing that HG-mediated increased LOX expression and activity inactivate AKT signaling, which triggers caspase-3 activation, thereby promoting apoptosis in RRECs, and that reducing abnormal LOX overexpression and increased activity improves AKT activation, protecting RRECs from HG-induced apoptosis. Moreover, this finding is supported by previous studies indicating that LOX upregulation impairs AKT activity^{26,27} contributing to apoptosis. These results derived from an in vitro model of hyperglycemia, a STZ-induced diabetes animal model, and a LOX^{+/-} animal model, suggest that abnormal LOX upregulation may play an important role in promoting the development of retinal vascular lesions associated with diabetic retinopathy.

Previously, we have shown that LOX expression is significantly increased in retinal endothelial cells under HG condition and in retinas of diabetic rats.¹⁶ Furthermore, our previous data suggest that increased LOX activity may lead to excessive cross-linking resulting in compact collagen fibrils, which in turn may compromise the ultrastructural integrity of the BM.¹⁶ Importantly, we have identified that HG-induced increase in LOX activity promotes excess cell monolayer permeability in retinal endothelial cells,¹⁶ providing a potential mechanistic insight into vascular leakage associated with thickened BM seen in diabetic retinopathy. While the association between LOX and formation of the BM is well established, the relationship between LOX overexpression and retinal vascular cell loss is unclear. The current study shows for the first time that excess LOX levels play a critical role in




FIGURE 4. BAPN treatment prevents HG-induced apoptosis. (A–C) Representative images of cells undergoing apoptosis (arrows): (A) Normal, (B) HG, (C) HG+BAPN. Scale bar: 50 μ m. Differential staining assay shows that inhibition of HG-induced increased LOX activity via BAPN treatment reduced the number of cells undergoing apoptosis. (D) Graphic illustration of cumulative data shows that inhibiting HG-induced increased LOX activity rescues RRECs from HG-induced apoptosis. Data are expressed as mean \pm SD. N versus HG; $P < 0.05$. **HG versus HG+BAPN; $P < 0.05$. $n = 4$.

triggering apoptosis and thereby promote retinal vascular cell loss.

Decreased AKT activity under HG or diabetic conditions^{37–40} leads to apoptosis.^{37,38,40} Importantly, findings from the current study indicate that HG-induced LOX upregulation leads to reduced AKT-Ser473 phosphorylation, promoting apoptosis. However, the exact mechanism of action mediating these changes underlying upregulated LOX expression is currently not well known. A study by Jeay et al.²⁶ suggests that LOX inhibits Ras signaling and prevents recruitment of AKT to the plasma membrane necessary for AKT activation. Another study reported that adenovirus-mediated LOX upregulation blocked AKT activation, promoting apoptosis.²⁷ Furthermore, LOX inhibition prevented apoptosis in volume overloaded hearts of rats.⁴¹ It is also interesting to note that LOX pro-peptide (LOX-PP), an 18-kD domain of LOX produced during proteolytic cleavage, can promote apoptosis by AKT inactivation.⁴² Therefore, it is conceivable that LOX-PP may also play a contributory role in triggering apoptosis under HG conditions. Taken together, these results indicate that HG-induced LOX upregulation may contribute to retinal vascular cell apoptosis, at least in part, by impairing AKT activation necessary for cell survival.

The role of LOX in maintaining retinal homeostasis and cell survival is only beginning to be understood. Interestingly, a recent study by Yang et al.⁴³ showed that LOX inhibition was associated with reduced nuclear factor- κ B (NF- κ B) activation. Importantly, NF- κ B activation has been shown to promote apoptosis in the context of diabetic retinopathy.^{44–46} Furthermore, HG-induced AKT inactivation can lead to reduced nitric oxide production,³⁷ which can inhibit proapoptotic NF- κ B signaling.³⁷ These findings indicate that HG can lead to sustained NF- κ B activation and reduce AKT signaling in endothelial cells, thereby contributing to vascular cell loss.³⁷ These cellular events may provide insight into a potential mechanism by which normalizing LOX expression may restore AKT activity, and thereby promote cell survival by inhibiting the proapoptotic NF- κ B signaling in retinal endothelial cells.




FIGURE 5. LOX downregulation restores AKT activity, and inhibits Bax and caspase-3 activation in diabetic LOX^{+/-} mouse retinas. (A) Representative WB image shows LOX, p-AKT, AKT, cleaved caspase-3, and β-actin expression in the retinas of WT, diabetic (DM), LOX^{+/-}, and diabetic LOX^{+/-} (DLOX^{+/-}) mice. (B) Graphic illustration of cumulative data shows that diabetes significantly increases LOX expression. (C) Graphic illustration of cumulative data shows that AKT activity is significantly decreased in diabetic mouse retinas. Interestingly, AKT activity is increased in DLOX^{+/-} mouse retinas compared to diabetic mouse retinas. Graphic illustration of cumulative data shows that (D) caspase-3 and (E) Bax activity are significantly reduced in DLOX^{+/-} mouse retinas compared to diabetic mouse retinas. Data are expressed as mean ± SD. *WT versus DM; $P < 0.05$. **DM versus DLOX^{+/-}; $P < 0.05$. ***WT versus LOX^{+/-}; $P < 0.05$. $n = 6$.

Findings from the current study suggest that HG-induced LOX overexpression contributes to accelerated cell loss associated with early-stage diabetic retinopathy, at least in part by AKT inactivation. These findings may offer an insight into potential mechanisms by which HG promotes apoptosis. The present study demonstrated that blocking HG-induced LOX upregulation might have beneficial effects including prevention of retinal vascular cell loss associated with diabetic retinopathy. Therefore, targeting LOX overexpression and/or increased activity could be a useful strategy for preventing vascular cell loss in diabetic retinopathy.

Acknowledgments

Presented in part at the 75th Scientific Sessions of the American Diabetes Association, Boston, Massachusetts, United States, June 2015.

Supported by National Eye Institute, National Institutes of Health Grants EY025528 (SR), HL53325, and HL105314 (RPM).

Disclosure: **D. Kim**, None; **R.P. Mecham**, None; **P.C. Trackman**, None; **S. Roy**, None

References

- Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. *Diabetes Care*. 2004;27(suppl 1):S84-S87.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27:1047-1053.
- Engerman RL. Pathogenesis of diabetic retinopathy. *Diabetes*. 1989;38:1203-1206.
- Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. *Diabetes*. 2002;51:3107-3112.
- Li W, Yanoff M, Liu X, Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. *Chin Med J (Engl)*. 1997;110:659-663.
- Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. *J Clin Invest*. 1996;97:2883-2890.
- Podesta F, Romeo G, Liu WH, et al. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. *Am J Pathol*. 2000;156:1025-1032.
- Cunha-Vaz J, Bernardes R. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. *Prog Retin Eye Res*. 2005;24:355-377.
- Beauchemin ML, Leuenberger PM, Babel J. Retinal capillary basement membrane thickness in spiny mice (*Acomys cahirinus*) with induced and spontaneous diabetes. *Invest Ophthalmol*. 1975;14:560-562.
- Bloodworth JM Jr. Diabetic microangiopathy. *Diabetes*. 1963;12:99-114.
- Hainsworth DP, Katz ML, Sanders DA, Sanders DN, Wright EJ, Sturek M. Retinal capillary basement membrane thickening in a porcine model of diabetes mellitus. *Comp Med*. 2002;52:523-529.

12. Roy S, Ha J, Trudeau K, Beglova E. Vascular basement membrane thickening in diabetic retinopathy. *Curr Eye Res.* 2010;35:1045-1056.
13. Beltramo E, Buttiglieri S, Pomero F, et al. A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. *Diabetologia.* 2003;46:409-415.
14. Roy S, Lorenzi M. Early biosynthetic changes in the diabetic-like retinopathy of galactose-fed rats. *Diabetologia.* 1996;39:735-738.
15. Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: mechanisms and consequences. *Curr Med Chem.* 2013;20:3218-3225.
16. Chronopoulos A, Tang A, Beglova E, Trackman PC, Roy S. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. *Diabetes.* 2010;59:3159-3166.
17. Sethi A, Wordinger RJ, Clark AE. Focus on molecules: lysyl oxidase. *Exp Eye Res.* 2012;104:97-98.
18. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. *Matrix Biol.* 1998;16:387-398.
19. Gelse K, Poschl E, Aigner T. Collagens-structure, function, and biosynthesis. *Adv Drug Deliv Rev.* 2003;55:1531-1546.
20. Poschl E, Schlotzer-Schrehardt U, Brachvogel B, Saito K, Ninomiya Y, Mayer U. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. *Development.* 2004;131:1619-1628.
21. Rucker RB, Kosonen T, Clegg MS, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. *Am J Clin Nutr.* 1998;67:996S-1002S.
22. Siegel RC, Pinnell SR, Martin GR. Cross-linking of collagen and elastin. Properties of lysyl oxidase. *Biochemistry.* 1970;9:4486-4492.
23. Trackman PC, Bedell-Hogan D, Tang J, Kagan HM. Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. *J Biol Chem.* 1992;267:8666-8671.
24. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. *Am J Physiol Heart Circ Physiol.* 2010;299:H1-H9.
25. Rimar D, Rosner I, Nov Y, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. *Arthritis Rheumatol.* 2014;66:726-730.
26. Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. *Mol Cell Biol.* 2003;23:2251-2263.
27. Xu X, Wang B, Xu Y. Expression of lysyl oxidase in human osteosarcoma and its clinical significance: a tumor suppressive role of LOX in human osteosarcoma cells. *Int J Oncol.* 2013;43:1578-1586.
28. Kaneda A, Wakazono K, Tsukamoto T, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. *Cancer Res.* 2004;64:6410-6415.
29. Sung FL, Cui Y, Hui EP, et al. Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. *Am J Cancer Res.* 2014;4:789-800.
30. Chronopoulos A, Trudeau K, Roy S, Huang H, Viores SA, Roy S. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. *Curr Eye Res.* 2011;36:747-753.
31. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. *J Biol Chem.* 2003;278:14387-14393.
32. Maki JM, Rasanen J, Tikkanen H, et al. Inactivation of the lysyl oxidase gene *Lox* leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. *Circulation.* 2002;106:2503-2509.
33. Bondareva A, Downey CM, Ayres F, et al. The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. *PLoS One.* 2009;4:e5620.
34. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A.* 1979;76:4350-4354.
35. Liegler TJ, Hyun W, Yen TS, Stites DP. Detection and quantification of live, apoptotic, and necrotic human peripheral lymphocytes by single-laser flow cytometry. *Clin Diagn Lab Immunol.* 1995;2:369-376.
36. McGahon AJ, Martin SJ, Bissonnette RP, et al. The end of the (cell) line: methods for the study of apoptosis in vitro. *Methods Cell Biol.* 1995;46:153-185.
37. Ho FM, Lin WW, Chen BC, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. *Cell Signal.* 2006;18:391-399.
38. Muto T, Tien T, Kim D, Sarthy VP, Roy S. High glucose alters cx43 expression and gap junction intercellular communication in retinal Müller cells: promotes Müller cell and pericyte apoptosis. *Invest Ophthalmol Vis Sci.* 2014;55:4327-4337.
39. Shao J, Yamashita H, Qiao L, Friedman JE. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. *J Endocrinol.* 2000;167:107-115.
40. Ye EA, Steinle JJ. miR-15b/16 protects primary human retinal microvascular endothelial cells against hyperglycemia-induced increases in tumor necrosis factor alpha and suppressor of cytokine signaling 3. *J Neuroinflammation.* 2015;12:44.
41. El Hajj MC, Voloshenyuk TG, Claudino MA, Bradley JM, Gardner JD. Lysyl oxidase inhibition in the volume overloaded heart prevents adverse collagen remodeling, apoptosis, and cardiac dysfunction. *FASEB J.* 2013;27:1128.1115.
42. Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH. Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. *J Cell Biochem.* 2010;111:1160-1168.
43. Yang X, Scott HA, Monickaraj F, et al. Basement membrane stiffening promotes retinal endothelial activation associated with diabetes. *FASEB J.* 2016;30:601-611.
44. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? *Free Radic Biol Med.* 1999;27:752-763.
45. Kowluru RA, Koppolu P, Chakrabarti S, Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. *Free Radic Res.* 2003;37:1169-1180.
46. Qin X, Zhang Z, Xu H, Wu Y. Notch signaling protects retina from nuclear factor-kappaB- and poly-ADP-ribose-polymerase-mediated apoptosis under high-glucose stimulation. *Acta Biochim Biophys Sin (Shanghai).* 2011;43:703-711.